Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Tag
  • C-His
    (2)
  • C-His-Avi
    (1)
  • N-6xHis
    (1)
TargetMol | Tags By Expression System
  • HEK293 Cells
    (3)
  • E. coli
    (1)
TargetMol | Tags By Species
  • Human
    (3)
  • Mouse
    (1)
TargetMol | Tags By SPR-compatible Buffer
  • Ready-to-use
    (3)
  • Buffer-exchangeable
    (1)
Filter
Search Result
Results for "

desmoglein3

" in TargetMol Product Catalog
  • Recombinant Protein
    4
    TargetMol | Recombinant_Protein
  • Antibody Products
    1
    TargetMol | Antibody_Products
TargetMolTargetMolCompare
DSG3 Protein, Human, Recombinant (E. coli, His)
DSG3, Desmoglein-3, CDHF6, Cadherin family member 6, 130 kDa pemphigus vulgaris antigen (PVA)
TMPH-01217
Expression system: E. coli
Length: 50-615, Extracellular Domain
Activity: Not Tested
  • Inquiry Price
20 days
Size
QTY
Buffer-exchangeable
TargetMolTargetMolCompare
DSG3 Protein, Mouse, Recombinant (His)
SG3, PVA, DSG-3, DSG3, Desmoglein-3, CDHF6
TMPK-00726
Expression system: HEK293 Cells
Length: 50-617, Partial
Activity: Not Tested
  • Inquiry Price
7-10 days
Size
QTY
SPR-compatible buffer
TargetMolTargetMolCompare
DSG3 Protein, Human, Recombinant (His)
SG3, PVA, DSG-3, DSG3, Desmoglein-3, CDHF6
TMPK-00871
Expression system: HEK293 Cells
Length: 50-615, Extracellular Domain
Activity: ELISA
  • Inquiry Price
7-10 days
Size
QTY
SPR-compatible buffer
TargetMolTargetMolCompare
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein, Human, MHC (His & Avi)
PVA, DSG-3, DSG3, DG3, Desmoglein-3, CDHF6
TMPK-01485
DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
  • Inquiry Price
7-10 days
Size
QTY
SPR-compatible buffer